Dilinda
Generic Name
Indacaterol
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| dilinda 150 mcg inhalation capsule | ৳ 35.00 | ৳ 350.00 |
Description
Overview of the medicine
Dilinda 150 mcg Inhalation Capsule contains Indacaterol, a long-acting beta2-adrenergic agonist (LABA). It is used for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). It helps to relax the muscles around the airways in the lungs, making them wider and making it easier to breathe.
Uses & Indications
Dosage
Adults
The recommended dose is one 150 mcg capsule once daily, inhaled using the specific inhaler device.
Elderly
No dosage adjustment is required in elderly patients.
Renal_impairment
No dosage adjustment is required in patients with renal impairment.
Hepatic_impairment
No dosage adjustment is required in patients with mild to moderate hepatic impairment.
How to Take
Dilinda 150 mcg Inhalation Capsule should only be administered by oral inhalation using the specific inhaler device provided. The capsule should not be swallowed. Follow the instructions for use provided with the inhaler device carefully.
Mechanism of Action
Indacaterol is an ultra-long-acting beta2-adrenergic agonist (ULABA). It works by stimulating beta2-adrenergic receptors in the bronchial smooth muscle, leading to relaxation of the smooth muscle, thus causing bronchodilation. This effect helps to open up the airways and improve airflow in the lungs.
Pharmacokinetics
Onset
Within 5 minutes after inhalation.
Excretion
Primarily excreted via the feces (major route) and to a lesser extent via urine.
Half life
The terminal half-life is approximately 40-52 hours.
Absorption
Rapidly absorbed into the systemic circulation following inhalation. Peak plasma concentrations are reached approximately 15-30 minutes after inhalation.
Metabolism
Primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT1A1) and, to a lesser extent, by cytochrome P450 3A4 (CYP3A4).
Side Effects
Contraindications
- •Hypersensitivity to indacaterol or any of the excipients.
- •Not indicated for the relief of acute bronchospasm.
Drug Interactions
Diuretics
May potentiate hypokalemia.
MAOIs/TCAs
May potentiate the cardiovascular effects of indacaterol.
Beta-blockers
May reduce the effect of indacaterol; concurrent use should generally be avoided.
QT-prolonging drugs
Use with caution due to potential for additive effects on QTc interval.
Other sympathomimetics
May potentiate adverse cardiovascular effects.
Storage
Store below 30°C in a dry place. Protect from moisture and light. Keep out of reach of children.
Overdose
Symptoms of overdose are typically those of excessive beta2-adrenergic stimulation, such as tachycardia, tremor, palpitations, headache, nausea, vomiting, drowsiness, and hypokalemia. Treatment is generally symptomatic and supportive.
Pregnancy & Lactation
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether indacaterol is excreted in human milk; caution should be exercised when administered to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture, specific expiry date mentioned on the packaging.
Availability
Pharmacies, hospitals
Approval Status
Approved by major regulatory bodies
Patent Status
Generic versions available, original patent expired
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
